Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

News | March 13, 2015

March 13, 2015 — Researchers at the University of North Carolina (UNC) School of Medicine have found the blood...

Point of Care Decision Support, anticoagulation software, PCDS AC, therapy

Image courtesy of Point of Care Decision Support

News | Clinical Decision Support | March 11, 2015

March 11, 2015 — Point of Care Anticoagulation software (PCDS AC) optimizes delivery of...

atrial fibrillation, women, seniors, guidelines, blood thinners, DCRI
Feature | March 09, 2015

March 9, 2015 — Nearly all women and people over 65 in the United States with...

Xarelto, rivaroxaban, Starter Pack, FDA, deep vein thrombosis, pulmonary embolis
Technology | March 04, 2015

March 4, 2015 — The U.S. Food and Drug Administration (FDA) has approved the Xarelto Starter Pack for...

News | February 26, 2015

February 26, 2015 — Patients who experienced a certain type of heart attack who received the...

nanoparticles, stroke, tPA, blood clot, magnetic, MRI, antiplatelet

Each nanoparticle is composed of an iron oxide core (red squares) that is swathed in albumin (grey) and the anti-clotting agent tPA (green). The iron oxide cubes are about 20 nm on a side.

News | February 26, 2015

February 26, 2015 — By loading magnetic nanoparticles with drugs and dressing them in biochemical camouflage,...

antiplatelet therapy, pharmaceuticals, cath lab, clinical trial, ticagrelor

Image courtesy of Vital Images

News | January 22, 2015

January 22, 2015 — AstraZeneca announced that the...

rivaroxaban, Xarelto, safety performance, Janssen, NVAF
Feature | January 21, 2015

January 21, 2015 — A new post-marketing study evaluating the safety of once-daily...

Blog | January 21, 2015

The America College of Cardiology has released its list of...

Image courtesy of ACC

Feature | January 14, 2015

January 14, 2015 — More than 10 percent of patients treated with...

Savaysa, Daiichi Sankyo, edoxaban, FDA, approval, NVAF, thromboembolism
Technology | January 13, 2015

January 12, 2015 — Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved...

News | January 07, 2015

January 7, 2015 — Discussions regarding late-breaking cardiovascular...

News | December 30, 2014

December 30, 2014 — Wearable technologies, possible changes to stenting practices, state legislation on energy...

News | December 23, 2014

December 23, 2014 — The most accessed research studies in the Journal of the American College of Cardiology (JACC)...

Alere, INRatio, INRatio2, PT/INR Monitor system, correction

Photo courtesy of Alere

News | December 16, 2014

December 16, 2014 — Alere Inc. has initiated a voluntary correction to inform United States users of the Alere...

Overlay Init